Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P54098

UPID:
DPOG1_HUMAN

ALTERNATIVE NAMES:
Mitochondrial DNA polymerase catalytic subunit; PolG-alpha

ALTERNATIVE UPACC:
P54098; Q8NFM2; Q92515

BACKGROUND:
The enzyme DNA polymerase subunit gamma-1, alternatively named PolG-alpha, is integral to the replication of mitochondrial DNA, maintaining mitochondrial genome integrity and supporting cellular energy demands.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting DNA polymerase subunit gamma-1 are implicated in a spectrum of mitochondrial diseases, such as Mitochondrial DNA depletion syndromes and Sensory ataxic neuropathy. Targeting the function of DNA polymerase subunit gamma-1 offers a promising avenue for the development of treatments for these mitochondrial dysfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.